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Stereotactic body radiotherapy (SBRT) is attracting 
substantial interest as a treatment option for selected 
patients with metastatic disease. It is reasonable to take a 
step back and take a look at where the field is now and what 
we can expect from this intervention. This presentation will 
focus on a number of contemporary clinical issues, including: 
what can be expected from SBRT at various anatomical sites; 
definitions of oligo-metastatic disease and their limitations; 
defining treatment goals in metastatic disease; lessons from 
published outcome data; a pragmatic approach to decision-
making in the clinic; is radiation technology driving the 
agenda? and; gathering evidence for the future. 
 
SP-0407  
Abdominal-pelvic targets 
M. Hoyer
1Aarhus University Hospital, Department of Oncology, 
Aarhus, Denmark 
1 
 
Patients with oligometastases from colo-rectal carcinoma 
(CRC) are often considered as candidates for surgical 
resection, radiofrequency ablation and SBRT and CRC often 
metastasize to the abdominal organs, especially to the liver. 
Therefore, abdominal oligo-metastases are often treated 
with SBRT. A relative large number of publications 
demonstrate outcome after SBRT for liver metastases that 
are almost as good as for lung metastases. Local control rates 
in both lung and liver are most often in the range 70-90% and 
survival rates are depending on tumor type and the selection 
of the patients. There are only few publications on SBRT of 
abdominal, non-liver oligometastases, but the few available 
publications indicate favourable local control as well for 
these patients. Most publications on SBRT for abdominal 
targets report a low risk of morbidity, but there are reports 
of relatively severe morbidity related to irradiation of the 
liver and the bowel, most often in terms of severe mucositis 
or intestinal ulceration. Treatment of abdominal targets is 
complex due to the multiple organs at risk. Treatment 
planning is based on a snapshot of the anatomy on a 
treatment planning CT-scan. 4DCT takes the intrafraction 
motion motion of the target into account, but we usually do 
not take the motion of bowel structures into account. CBCT is 
used to correct for set-up errors of the target, but organs at 
risk are less often considered. This may lead to unintended 
high doses to the organs at risk and side effects that were not 
expected from the treatment planning. 
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Recent progress has been made in oncology with new drug 
targeting immune system. Ipilimumab which targets CTLA-4 
has been the first one approved in melanoma. Another way to 
block the deleterious cascade of T-lymphocyte inhibition is to 
block an extracellular target, namely Programmed Death 
Receptor-1 (PD-1). PD-1 is a cell surface receptor expressed 
by T cells, B cells, and myeloid cells, and member of the 
CD28 family involved in T cell regulation. PD-1 pathway is 
activated by receptor binding to ligands (PD-L1 or PD-L2) and 
its physiological role is to prevent uncontrolled immune 
activation during chronic infection or inflammation. In 
cancer, activation of PD-1 pathway can suppress antitumor 
immunity. In mouse models, antibodies blocking PD-1/PD-L1 
interaction lead to tumor rejection. In clinical trials, 
targeting PD-1 pathway using human monoclonal antibody 
such as nivolumab, which blocks binding of PD-1 to PD-L1 and 
PD-L2, showed promising results in metastatic solid tumors 
with durability of objective responses, and sustained overall 
survival (Topalian and al, NEJM 2012). Phase I studies showed 
a potential better safety profile of anti-PD-1/PD-L1 agents in 
comparison with ipilimumab. Following, anti-PD-1/PD-L1 
drugs have been developed at a phenomenal speed, taking 
just three years from the first clinical trials to approval. At 
now, anti-PD-1 nivolumab and pembrolizumab are approved 
in melanoma and NSLCC... There is a strong rationale for 
using anti-PD-1/PD-L1 agents in HNSCC. Tumor-infiltrating 
lymphocytes (TILs) which are required for PD-1 blockade, and 
PD-L1 expression are present in HPV+ and HPV negative 
HNSCC. There is a correlation between infiltration by CD8 
cells and response to CRT, and between PD-L1 expression and 
survival. The high number of specific mutations observed in 
HNSCC could be a mechanism of immunogenicity. Results of 
phase I studies testing anti-PD-1/PD-L1 agents in HNSCC 
patients have been recently reported with promising results 
in terms of efficacy with prolonged responses. During ASCO 
2014 meeting, Seiwert et al. presented first results of a 
phase Ib study of pembrolizumab in recurrent/metastatic 
(R/M) HNSCC patients. Patients with ≥1% PD -L1 
immunohistochemistry expression in tumor cells or stroma 
were enrolled in the study. The anti-tumor effect was 
observed both in patients with HPV-positive and HPV-
negative tumors. The duration of these responses was 
impressive, some already lasting over one year (Seiwert TY et 
al., ASCO 2014, CSS 6011). Updated data on a expanded 
cohort have been presented at last ASCO 2015 meeting. 132 
(81 HPV+) R/M HNSCC patients were treated with 
prembrolizumab 200 mg Q3W regardless of HPV or PD-L1 
status. 78% received at least one line of chemotherapy. 
Tolerance was good (9.8% of grade 3-5 adverse events). 
Objective response rate was 25%, stable disease rate was 25% 
with long-lasting responses (Seiwert TY, et al. J Clin Oncol. 
2015;33(suppl): LBA6008). First results of a phase I study 
evaluating the safety and efficacy of an anti-PD-L1 agent, 
durvalumab (MEDI4736), have been presented at ESMO 2014 
congress (M. Fury M et al., abstr 988PD, ESMO 2014). 
MEDI4736 is a human IgG1 mAb, engineered to prevent ADCC 
activity, that blocks PD-L1 binding to PD-1 and CD-80. 50 pts 
with HNSCC, with median 3 prior treatments received median 
3 doses of MEDI4736 10 mg/kg q2w. Treatment-related 
